Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.69 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.67 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.47 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440162 | 0.90 | PIK3CA (0.57) | PIK3CAMAPKAPK2CAMKK1CAMKK2ACVR1 | |
| SCHEMBL9709110 | 0.88 | PIK3CA (0.87) | PIK3CAMAPKAPK2CAMKK1CAMKK2ACVR1 | |
| SCHEMBL30439681 | 0.81 | PIK3CA (0.55) | PIK3CAMAPKAPK2CAMKK1CAMKK2ACVR1 | |
| SCHEMBL30440085 | 0.79 | PSMB5 (0.56) | PIK3CAMAPKAPK2ACVR1AKT1MAPT | |
| SCHEMBL30440201 | 0.78 | PSMB5 (0.52) | PIK3CAMAPKAPK2AKT1 | |
| SCHEMBL30439475 | 0.78 | PIK3CA (0.57) | PIK3CAMAPKAPK2CAMKK1CAMKK2ACVR1 | |
| SCHEMBL29903866 | 0.77 | PSMB5 (0.51) | PIK3CAMAPKAPK2 | |
| SCHEMBL29903844 | 0.77 | PSMB5 (0.51) | PIK3CAMAPKAPK2 | |
| SCHEMBL29903858 | 0.77 | PSMB5 (0.51) | PIK3CAMAPKAPK2 | |
| SCHEMBL19009538 | 0.77 | MAPKAPK2 (0.47) | PIK3CAMAPKAPK2CAMKK1CAMKK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | FABP4, FABP1, FABP3 | PIK3CA 3770/4885MAPKAPK2 1122/4885CAMKK1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.